XIGDUO™ (dapagliflozin and metformin hydrochloride) approved in the European Union for type 2 diabetes
AstraZeneca and Bristol-Myers Squibb announced that Xigduo™ has been granted…
22 January 2014 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb announced that Xigduo™ has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union...